SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

Core Insights - Sera Prognostics Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, highlighting the company's latest achievements [1] - The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information [1][3] Company Overview - Sera Prognostics is dedicated to enhancing the lives of women and babies via precision pregnancy care, aiming to provide early pregnancy information to improve health outcomes and reduce healthcare costs [3] - The company has a robust pipeline of diagnostic tests, particularly the PreTRM® Test, which predicts the risk of spontaneous premature delivery [3][5] Preterm Birth Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4] PreTRM® Test Details - The PreTRM® Test is the only broadly validated blood-based biomarker test that provides early and accurate risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test allows physicians to identify women at increased risk for preterm birth between weeks 18 and 20 of pregnancy, facilitating personalized clinical decisions [5]